Many drug candidates fail in later stages of development due to unacceptable toxicity, often linked to the limited predictive capabilities of early-stage screening models. However, three-dimensional (3D) organoids present a promising alternative, offering enhanced accuracy in in vitro assays and proving valuable for pre-clinical testing.
Intestinal toxicity is one of the most common side effects of anti-cancer drugs, limiting the dosages that can be safely administered to patients. 3D organoid models allow for effective assessment of these toxic effects, providing crucial data throughout the drug development process.
The use of automated high-content imaging further improves throughput, expanding the scope of toxicity information, particularly in complex 3D biological systems. This study demonstrates the ability to evaluate and quantify toxic effects in intestinal organoids using high-content imaging techniques.
The method developed focuses on assessing toxicity in 3D mouse intestinal organoids cultured in Matrigel domes, where phenotypic effects of 10 compounds were tested at varying concentrations.
Molecular Devices, a leading provider of high-performance life science technology, contributed to the development of this method. The company’s innovative platforms for high-throughput screening and cellular analysis support advancements in fields like cancer research and drug development.
Related Topics
